Study shows increased IPL sessions increased response rate of treatment in moderate-to-severe MGD

News
Article

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

Closeup of eyelid inflammation Image Credit: AdobeStock/OHishi_Foto

Image Credit: AdobeStock/OHishi_Foto

A new study reports that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.1 The study was conducted by Yang Lu, MD, first author, and colleagues from the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, and the NHC Key Laboratory of Myopia, Fudan University, both in Shanghai, China.

The clinicians conducted this retrospective study to determine if 90 Asian adult patients with moderate–to–severe MGD could benefit from increasing the number of IPL treatment sessions. Moderate-to-severe MGD is classified as stages 3 to 4.

The patients were divided into 2 groups: 30 patients in group 1 underwent 5 sessions of IPL and 63.3% of them also had expression of the meibomian glands, and 60 patients in group 2 underwent 3 sessions of IPL and 60% also underwent meibomian gland expression.

Results of group comparison

The investigators found that in both groups the symptoms and most clinical indices improved after the IPL treatment sessions finished.

They did not observe a statistical difference in any of the improvement levels of all symptomatic and physical indices, including the ocular surface disease index, tear film break–up time, Demodex, corneal staining, meibum quality, meibomian gland expressibility, and MGD stage (p ≥ 0.05 for all comparisons) between the 2 groups at any time, that is month by month and at the final visit.

However, the investigators did see that the response rate in group 1 after the 5 session of IPL increased compared to the patients in group 2 who were treated with 3 session of IPL treatment (70.0% vs. 63.33%, respectively).

The authors commented, “Increasing the number of IPL sessions is beneficial for patients with moderate-to-severe MGD to increase the response rate of treatment rather than the improvement level. However, there is no need for patients who respond well to a routine number of IPL treatments to undergo additional IPL sessions.”

Reference:
  1. Lu Y, Gong L, Yin Y. Need to increase the number of intense pulsed light (IPL) treatment sessions for patients with moderate to severe meibomian gland dysfunction (MGD). Curr Eye Res. 2024;49:362–367; https://doi.org/10.1080/02713683.2023.2297344

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Brett Bielory, MD, at ASCRS 2025
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
© 2025 MJH Life Sciences

All rights reserved.